Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Athersys Inc.

www.athersys.com

Latest From Athersys Inc.

J.P. Morgan Roundtable: The Regulatory Role In Accelerating Complex Therapies

Companies working on cell and gene therapies and novel approaches to neurological diseases participated in a roundtable discussion during the J.P. Morgan Healthcare Conference about how regulators are supporting novel modalities, which in turn improves investor and partner sentiment.

Regenerative Medicine Research and Development Strategies

J.P. Morgan Roundtable: The Regulatory Role In Accelerating Complex Therapies

Part 3: Scrip spoke with companies working on cell and gene therapies and novel approaches to neurological diseases during the J.P. Morgan Healthcare Conference about how regulators are supporting novel modalities, which in turn improves investor and partner sentiment.

Business Strategies Research and Development Strategies

J.P. Morgan Roundtable: Making Deals And Managing Alliances As Technologies Advance

Part 2: Scrip spoke with companies working on cell and gene therapies and novel neurology approaches during the J.P. Morgan Healthcare Conference about the dos and don'ts of deal-making as they advance innovative programs into the clinic and beyond.

Deals StartUps and SMEs

J.P. Morgan Roundtable: Financing Challenges, And Opportunities, For Complex Therapies

Part 1: Scrip spoke with companies working on cell and gene therapies and novel neuroscience platforms – areas difficult to finance in the past, but seeing increasing investor interest – about funding challenges and opportunities in 2019.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Immune Disorders
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • BTHC VI Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Athersys Inc.
  • Senior Management
  • Gil Van Bokkelen, PhD, Chmn. & CEO
    John Harrington, PhD, EVP, CSO
    Laura Campbell, SVP, Fin.
    William Lehmann, JD, President and COO
    Manal Morsy, MD, PhD, SVP, Head of RA
    Robert Mays, PhD, VP Regenerative Medicine. Head Neuroscience
    Anthony Ting, PhD, VP Regenerative Medicine. Head Cardiopulmonary
    Raymond Starling, PhD, VP, Clinical Dev & Ops
  • Contact Info
  • Athersys Inc.
    Phone: (216) 431-9900
    3201 Carnegie Ave.
    Cleveland, OH 44115-2634
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register